Agents Under Study
Ehsan Rahimy, Elham Rahimy, Anthony Joseph · CRC Press eBooks · 2024
The advent of intravitreal anti-vascular endothelial growth factor (VEGF) therapy has undoubtedly revolutionized the field of ophthalmology and how physicians manage many potentially debilitating retinal conditions. In the recently published 5-year outcomes with anti-VEGF therapy from the Comparison of Age-Related Macular Degeneration Treatment Trials, a remarkable 50% of follow-up participants had visual acuity of 20/40 or better; however, 20% of individuals had acuity of 20/200 or worse. 1 While this represents a significant improvement over previous natural history studies prior to the commencement of the anti-VEGF era, it is a reminder that much work remains to be accomplished.
Cited by 0 works. doi:10.1201/9781003522577-5